

## HKVCA Brownbag Luncheon Talk – 20 April, 2017

### The Latest Trends in Biotechnology and the Most Effective Way to Commercialize the Academic Projects




**Bosun Hau**, *Managing Director and Partner*, Sailing Capital

Bosun Hau is a Managing Director and Partner at Sailing Capital, a global private equity firm leveraging unique government and corporate relationships in China. He has nearly 15 years of healthcare industry experience, primarily as an investor in both private and publicly-listed companies. Prior to joining Sailing in 2015, Mr. Hau was a Partner at MVM Life Science Partners in Boston and London. Previously, he was a sell-side equity analyst covering medical technology and pharmaceuticals for JP Morgan Securities In New York. He also has experience as a management consultant with McKinsey & Company in Southeast Asia and as a venture capitalist with S.R. One, GlaxoSmithKline's corporate venture group. He began his career at Eli Lilly & Company in sales and marketing. Mr. Hau is currently, or has been, a Board Director for many emerging and leading healthcare companies. He also is a Board Overseer of Beth Israel Deaconess Medical Center in Boston, a major teaching hospital of Harvard Medical School. Mr. Hau holds an MBA from the Wharton School at the University of Pennsylvania and a Master's Degree in Biotechnology from Johns Hopkins University. He is a triple-bachelor's degree recipient from the University of Arizona.



**Judith Li**, *Partner*, Lilly Asia Ventures

Judith J. Li, is a Partner at Lilly Asia Ventures (LAV), based in Hong Kong / Shanghai and focused on early and growth stage investments across biopharmaceuticals, medical devices, and diagnostics both domestically and cross-border. Judith holds board appointments at a variety of LAV's portfolio companies including Nextcure, Crown Biosciences, Just Biotherapeutics, and Veritas Genetics. Her prior experience includes McKinsey's New York office, hospital administration at Partners Healthcare, and co-founding an interventional nephrology medical device venture. Judith holds a B.A. in Neurobiology from Harvard and M.B.A. from Harvard Business School, and currently resides in Hong Kong with her husband Ben, splitting her time between Hong Kong, Shanghai, and the Bay Area.



**Professor Kenneth Lee**, B.Sc., Ph.D., MIBIOL, CIBIOL, *Professor and Chief, Stem Cell and Regeneration Thematic Research Program, School of Biomedical Sciences, Chinese University of Hong Kong*

Professor Lee is the Professor and Chief Stem Cell and Regeneration Thematic Research Program, School of Biomedical Sciences at the Chinese University of Hong Kong (CUHK). He is also Director, Key Laboratory for Regenerative Medicine, Ministry of Education, China, and Director of the Joint CUHK-University of Southampton Laboratory for Stem Cell and Regenerative Medicine. Educated in the United Kingdom, he has over 30 years of research and teaching experiences, published 139 scientific papers and awarded 3 US patents. His research interests, among which many have commercial values, include the discovery of small molecules that induce somatic cells into become pluripotent stem cells, molecular biology of embryo development, cardiac and skeletal muscle regeneration, BRE gene in stem cell and cancer biology, and drug discovery for treatment of liver fibrosis

In 2015, Professor Lee found and has been the CEO of StapWorks Stem Cell Limited which markets Programin, a patented stem cell invention licensed with the CUHK. Stapworks' performance was recognized by the Hong Kong Federation of Innovative Technologies and Manufacturing Industries (FITMI) and Bank of China and was a Bronze Award winner in 2015. Personally, Professor Lee has also won many other awards including the prestigious Diamond Jubilee International Visiting Fellowship, University of Southampton (2014 – 2017). Moreover, he is a Prestigious Professor at the Chinese Academy of Science and Visiting Professor at Robert Gordon University.